Document:

Exhibit 4.26

 

ISRAELI SHARE OPTION PLAN

 

 

 

CAN-FITE BIOPHARMA LTD.

 

THE 2003 ISRAELI SHARE OPTION PLAN

 

(In compliance with Amendment No. 132 of the Israeli
Tax Ordinance, 2002)

 

    	1

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

TABLE OF CONTENTS

 

	1. PURPOSE OF THE ISOP	3
	 	 
	2. DEFINITIONS	3
	 	 
	3. ADMINISTRATION OF THE ISOP	6
	 	 
	4. DESIGNATION OF PARTICIPANTS	7
	 	 
	5. DESIGNATION OF OPTIONS PURSUANT TO SECTION 102 	8
	 	 
	6. TRUSTEE	8
	 	 
	7. SHARES RESERVED FOR THE ISOP	9
	 	 
	8. PURCHASE PRICE	10
	 	 
	9.  ADJUSTMENTS	10
	 	 
	10. TERM AND EXERCISE OF OPTIONS	12
	 	 
	11. VESTING OF OPTIONS	13
	 	 
	12. PURCHASE FOR INVESTMENT	14
	 	 
	13. SHARES SUBJECT TO RIGHT OF FIRST REFUSAL	14
	 	 
	14. DIVIDENDS	14
	 	 
	15. RESTRICTIONS ON ASSIGNABILITY AND SALE OF OPTIONS	15
	 	 
	16. EFFECTIVE DATE AND DURATION OF THE ISOP	15
	 	 
	17. AMENDMENTS OR TERMINATION	15
	 	 
	18. GOVERNMENT REGULATIONS	16
	 	 
	19. CONTINUANCE OF EMPLOYMENT	16
	 	 
	20. GOVERNING LAW & JURISDICTION	16
	 	 
	21. TAX CONSEQUENCES	16
	 	 
	22. NON-EXCLUSIVITY OF THE ISOP	17
	 	 
	23. MULTIPLE AGREEMENTS	17
	 	 
	24. LOCK-UP	17

 

    	2

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

This plan, as amended from time
to time, shall be known as Can-fite Biopharma Ltd 2003 Israeli Share Option Plan (the “ISOP”).

 

		1.	PURPOSE OF THE ISOP

 

The ISOP is intended to provide
an incentive to retain, in the employ of the Company and its Affiliates (as defined below), persons of training, experience, and
ability, to attract new employees, directors, consultants, service providers and any other entity which the Board shall decide
their services are considered valuable to the Company, to encourage the sense of proprietorship of
such persons, and to stimulate the active interest of such persons in the development and financial success of the Company by providing
them with opportunities to purchase shares in the Company, pursuant to the ISOP approved by the Board.

 

		2.	DEFINITIONS

 

For purposes of integrating the
ISOP and related documents (including the Option Agreement and its appendixes), the following definitions
shall apply:

 

		2.1	“Affiliate” means any “employing company” within the meaning of
Section 102(a) of the Ordinance.

 

		2.2	“Approved 102 Option” means an Option granted pursuant to Section 102(b) of
the Ordinance and held in trust by a Trustee for the benefit of the Optionee.

 

		2.3	“Board” means the Board of Directors of the Company.

 

		2.4	“Capital Gain Option (CGO)” means an Approved 102 Option elected and designated
by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance.

 

		2.5	“Cause” means, henceforth and hereinafter (i) conviction of any felony involving
moral turpitude or affecting the Company; (ii) any refusal to carry out a reasonable directive of the Company’s CEO, Board
or the Optionee’s direct supervisor, which involves the business of the Company or its affiliates and was capable of being
lawfully performed; (iii) embezzlement of funds of the Company or its affiliates; (iv) any breach of the Optionee’s fiduciary
duties or duties of care of the Company; including without limitation disclosure of confidential information of the Company; and
(v) any conduct (other than conduct in good faith) reasonably determined by the Board to be materially detrimental to the Company.

 

		2.6	“Chairman” means the chairman of the Committee.

 

		2.7	“Committee” means a share option compensation committee appointed by the Board,
which shall consist of no fewer than two members of the Board.

 

    	3

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		2.8	“Company” means Can-fite Biopharma Ltd, an Israeli company.

 

		2.9	“Companies Law” means the Israeli Companies Law 5759-1999, as now in effect
or as hereafter amended.

 

		2.10	“Controlling Shareholder” shall have the meaning ascribed to it in Section 32(9)
of the Ordinance.

 

		2.11	“Date of Grant” means the date determined by the Board or authorized Committee
as seth forth in Exhibit B to the Option Agreement.

 

		2.12	Employee” means a person who is employed by the Company or its Affiliates, including
an individual who is serving as a director or an office holder, but excluding Controlling Shareholder.

 

		2.13	“Expiration date” means the date upon which an Option shall expire, as set forth
in Section 10.2 of the ISOP.

 

		2.14	“Fair Market Value” means as of any date, the value of a Share determined as
follows:

 

(i)
If the Shares are listed on any established stock exchange or a national market system, including without limitation the NASDAQ
National Market system, or the NASDAQ SmallCap Market of the NASDAQ Stock Market, the Fair Market Value shall be the closing sales
price for such Shares (or the closing bid, if no sales were reported), as quoted on such exchange or system for the last market
trading day prior to time of determination, as reported in the Wall Street Journal, or such other source as the Board deems
reliable. Without derogating from the above, solely for the purpose of Section 102(b)(3) of the Ordinance, if at the Date of
Grant the Company’s shares are listed on any established stock exchange or a national market system or if the Company’s
shares will be registered for trading within ninety (90) days following the Date of Grant, the Fair Market Value of a Share at
the Date of Grant shall be determined in accordance with the average value of the Company’s shares on the thirty (30) trading
days preceding the Date of Grant or on the thirty (30) trading days following the date of registration
for trading, as the case may be;

 

(ii) If the Shares are regularly
quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value shall be the mean between the
high bid and low asked prices for the Shares on the last market trading day prior to the day of determination,
or;

 

(iii) In the absence of an established
market for the Shares, the Fair Market Value thereof shall be determined in good faith by the Committee.

 

		2.15	“IPO” means the initial public offering of the Company’s shares.

 

    	4

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		2.16	“ISOP” means this 2003 Israeli Share Option Plan.

 

		2.17	“ITA” means the Israeli Tax Authorities.

 

		2.18	“Non-Employee” means a consultant, adviser, service provider, Controlling Shareholder
or any other person who is not an Employee.

 

		2.19	“Ordinary Income Option (OIO)” means an Approved 102 Option elected and designated
by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) of the
Ordinance.

 

		2.20	“Option” means an option to purchase one or more Shares of the Company pursuant
to the ISOP.

 

		2.21	“102 Option” means any Option granted to Employees pursuant to Section 102 of
the Ordinance.

 

		2.22	“3(i) Option” means an Option granted pursuant to Section 3(i) of the Ordinance
to any person who is Non-Employee.

 

		2.23	“Optionee” means a person who receives or holds an Option under the ISOP.

 

		2.24	“Option Agreement” means the share option agreement between the Company and
an Optionee that evidences and sets out the terms and conditions of an Option.

 

		2.25	“Ordinance” means the 1961 Israeli Income Tax Ordinance [New Version] 1961 as
now in effect or as hereafter amended.

 

		2.26	“Purchase Price” means the price for each Share subject to an Option.

 

		2.27	“Section 102” means section 102 of the Ordinance as now in effect or as hereafter
amended.

 

		2.28	“Share” means the ordinary share, NIS 0.01 par value each, of the Company.

 

		2.29	“Successor Company” means any entity the Company is merged to or is acquired
by, in which the Company is not the surviving entity.

 

		2.30	“Transaction” means (i) merger, acquisition or reorganization of the Company
with one or more other entities in which the Company is not the surviving entity, (ii) a sale of all or substantially all
of the assets of the Company.

 

		2.31	“Trustee” means any individual appointed by the Company to serve as a trustee
and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance.

 

    	5

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		2.32	“Unapproved 102 Option” means an Option granted pursuant to Section 102(c) of
the Ordinance and not held in trust by a Trustee.

 

		2.33	“USSOP” means the Company’s 2002 US Share Option Plan.

 

		2.34	“Vested Option” means any Option that has already been vested according to the
Vesting Dates.

 

		2.35	“Vesting Dates” means, as determined by the Board or authorized Committee, the
date as of which the Optionee shall be entitled to exercise the Options or part of the Options, as set forth in section
11 of the below.

 

		3.	ADMINISTRATION OF THE ISOP

 

		3.1	The Board shall have the power to administer the ISOP either directly or upon the recommendation
of the Committee. Notwithstanding the above, the Board shall automatically have residual authority if no Committee shall be constituted
or if such Committee shall cease to operate for any reason whatsoever.

 

		3.2	The Committee shall select one of its members as its Chairman and shall hold its meetings at such
times and places as the Chairman shall determine. The Committee shall keep records of its meetings and shall make such rules and
regulations for the conduct of its business, as it shall deem advisable.

 

		3.3	The Committee shall have the power to recommend to the Board and the Board shall have the full
power and authority to: (i) designate Optionees; (ii) determine the terms and provisions of the respective Option Agreements (which
need not be identical) including, but not limited to, the number of Shares in the Company to be covered by each Option, provisions
concerning the time and the extent to which the Options may be exercised and the nature and duration of restrictions as to the
transferability or restrictions constituting substantial risk of forfeiture; (iii) accelerate the right of an Optionee to exercise
in whole or in part, any previously granted Option; (iv) determine the Fair Market Value of the Shares covered by each Option;
(v) to interpret the provisions and supervise the administration of the ISOP (vi) to make an election as to the type of Approved
102 Option; (vii) designate the type of Options granted; and (viii) to make all other determinations deemed necessary or advisable
for the administration of the ISOP, including, without limitation, to adjust the terms of the ISOP or any Option Agreement so as
to reflect (a) changes in applicable laws and (b) the laws of other jurisdictions within which the Company wishes to grant Options.

 

		3.4	Notwithstanding the above, the Committee shall not be entitled to grant Options to the Optionees,
however, it will be authorized to issue Shares underlying Options which have been granted by the Board and duly exercised pursuant
to the provisions herein in accordance with section 112(a)(5) of the Companies Law.

 

    	6

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		3.5	The Board shall have the authority to grant, at its discretion, to the holder of an outstanding
Option, in exchange for the surrender and cancellation of such Option, a new Option having a purchase price equal to, lower
than or higher than the Purchase Price of the original Option so surrendered and canceled and containing
such other terms and conditions as the Committee may prescribe in accordance with the provisions of the ISOP.

 

		3.6	Subject to the Company’s Articles of Association, all decisions and selections made by the
Board or the Committee pursuant to the provisions of the ISOP shall be made by a majority of its members except that no member
of the Board or the Committee shall vote on, or be counted for quorum purposes, with respect to any proposed action of the Board
or the Committee relating to any Option to be granted to that member. Any decision reduced to writing shall be executed in accordance
with the provisions of the Company’s Articles of Association, as the same may be in effect from time to time.

 

		3.7	The interpretation and construction by the Committee of any provision of the ISOP or of any Option
Agreement hereunder shall be final and conclusive unless otherwise determined by the Board.

 

		3.8	Subject to the Company’s Articles of Association and the Company’s decision, and to
all approvals legally required, including, but not limited to the provisions of the Companies Law, each member of the Board or
the Committee shall be indemnified and held harmless by the Company against any cost or expense (including counsel fees) reasonably
incurred by him, or any liability (including any sum paid in settlement of a claim with the approval of the Company) arising out
of any act or omission to act in connection with the ISOP unless arising out of such member's own fraud or bad faith, to the extent
permitted by applicable law. Such indemnification shall be in addition to any rights of indemnification the member may have as
a director or otherwise under the Company's Articles of Association, any agreement, any vote of shareholders or disinterested directors,
insurance policy or otherwise.

 

		4.	DESIGNATION OF PARTICIPANTS

 

		4.1	The persons eligible for participation in the ISOP as
Optionees shall include any Employees and/or Non-Employees of the Company or of any Affiliate; provided,
however, that (i) Employees may only be granted 102 Options; and (ii) Non-Employees and/or
Controlling Shareholders may only be granted 3(i) Options.

 

		4.2	The grant of an Option hereunder shall neither entitle the Optionee to participate nor disqualify
the Optionee from participating in, any other grant of Options pursuant to the ISOP or any other option or share plan of the Company
or any of its Affiliates.

 

		4.3	Notwithstanding anything in the ISOP to the contrary, all grants of Options to directors and office
holders ("Nosei Misra" as such term is defined in the Companies Law) shall be authorized and implemented in accordance
with the provisions of the Companies Law or any successor act or regulation, as in effect from time to time.

 

    	7

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		5.	DESIGNATION OF OPTIONS PURSUANT TO SECTION 102

 

		5.1	The Company may designate Options granted to Employees pursuant to Section 102 as Approved 102
Options or as Unapproved 102 Options.

 

		5.2	The grant of Approved 102 Options shall be made under this ISOP adopted by the Board, and shall
be conditioned upon the approval of this ISOP by the ITA.

 

		5.3	Approved 102 Options may either be classified as Capital Gain Options (“CGOs”)
or Ordinary Income Options (“OIOs”).

 

		5.4	No Approved 102 Option may be granted under the ISOP to any eligible Employee, unless and until,
the Company’s election of the type of Approved 102 Option as CGO or as OIO that will be granted to Employees (the “Election”),
is appropriately filed with the ITA. Such Election shall become effective beginning the first Date of Grant of an Approved 102
Option under this ISOP and shall remain in effect until the end of the year following the year in which the Company first granted
Approved 102 Options. The Election shall obligate the Company to grant only the type of Approved 102 Option it has elected, and
shall apply to all Optionees who were granted Approved 102 Options during the period indicated herein, all in accordance with the
provisions of Section 102(g) of the Ordinance. For the avoidance of doubt, such Election shall not prevent the Company from granting
Unapproved 102 Options simultaneously.

 

		5.5	For the avoidance of doubt, the designation of Approved 102 Options and Unapproved 102 Options
shall be subject to the terms and conditions of Section 102 of the Ordinance and the regulations promulgated thereunder.

 

		6.	TRUSTEE

 

		6.1	Approved 102 Options, which shall be granted under the ISOP and/or any Shares allocated or issued
upon exercise of such Approved 102 Options and/or other shares received subsequently following any realization of rights, including
without limitation bonus shares, shall be allocated or issued to the Trustee and held for the benefit of the Optionees, for such
period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder. In the case
the requirements for Approved 102 Options are not met, then the Approved 102 Options shall be treated as Unapproved 102 Options,
all in accordance with the provisions of Section 102 and regulations promulgated thereunder.

 

		6.2	Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or
issued upon exercise of Approved 102 Options prior to the full payment of the Optionee’s tax liabilities arising from Approved
102 Options which were granted to him and/or any Shares allocated or issued upon exercise of such
Options.

 

    	8

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		6.3	With respect to any Approved 102 Option, subject to the provisions of Section 102 and any rules
or regulation or orders or procedures promulgated thereunder, an Optionee shall not be entitled to sell or release from trust any
Share received upon the exercise of an Approved 102 Option and/or any share received subsequently following any realization of
rights, including without limitation, bonus shares, until the lapse of the holding period required under Section 102 of the Ordinance

 

		6.4	Upon receipt of an Approved 102 Option, the Optionee will sign an undertaking to release the Trustee
from any liability in respect of any action or decision duly taken and bona fide executed in relation with the ISOP, or any Approved
102 Option or Share granted to him thereunder.

 

		7.	SHARES RESERVED FOR THE ISOP; RESTRICTION THEREON

 

		7.1	The Company has reserved ______________ (                 )
authorized but unissued Shares, for the purposes of the ISOP and the USSOP and for the purposes of similar future plans, subject
to adjustment as set forth in Section 9 below. Any Shares which remain unissued and which are not subject to the outstanding Options
at the termination of the ISOP shall cease to be reserved for the purpose of the ISOP, but until termination of the ISOP the Company
shall at all times reserve sufficient number of Shares to meet the requirements of the ISOP. Should any Option for any reason expire
or be canceled prior to its exercise or relinquishment in full, the Shares subject to such Option may again be subjected to an
Option under the ISOP or under the Company’s other share option plans.

 

		7.2	Each Option granted pursuant to the ISOP, shall be evidenced by a written Option Agreement between
the Company and the Optionee, in such form as the Board or the Committee shall from time to time approve. Each Option Agreement
shall state, inter-alia, the number of Shares to which the Option relates, the type of Option granted (whether a
CGI, OIO, Unapproved 102 Option or a 3(i) Option), the Vesting Dates, the Purchase Price per share, the Expiration Date and such
other terms and conditions as the Committee or the Board in its discretion may prescribe, provided that they are consistent with
this ISOP.

 

    	9

    	 

    

  

ISRAELI SHARE OPTION PLAN

 

 

  

		7.3	Until the consummation of an IPO, the Shares shall be
voted by an irrevocable proxy (the”Proxy”), such Proxy to be assigned to the CEO of the Company (the “Proxy
Holder”). The Proxy Holder shall vote all such shares subject to the Proxy, at any meeting of the shareholders of the
Company, pro rata to the votes of all other shares actually voted at such meeting, so that the shares subject to the proxy shall
not influence in any way the vote of shares of the Company. The Proxy Holder shall be indemnified and held harmless by the Company
against any cost or expense (including counsel fees) reasonably incurred by him/her, or any liability (including any sum paid
in settlement of a claim with the approval of the Company) arising out of any act or omission to act in connection with the voting
of such Proxy unless arising out of such member’s own fraud or bad faith, to the extent permitted by applicable law. Such indemnification
shall be in addition to any rights of indemnification the person(s) may have as a director or otherwise under the Company’s Articles
of Association, any agreement, any vote of shareholders or disinterested directors, insurance policy or otherwise.

 

		8.	PURCHASE PRICE

 

		8.1	The Purchase Price of each Share subject to an Option
shall be determined by the Committee in accordance with applicable law, subject to any guidelines as may be determined by the
Board from time to time. Each Option Agreement will contain the Purchase Price determined for each Optionee.

 

		8.2	The Purchase Price shall be payable upon the exercise
of the Option in a form satisfactory to the Committee, including without limitation, by cash or check. The Committee shall have
the authority to approve in specific cases other means of payment or to postpone the date of payment on such terms as it may determine.

 

		8.3	The Purchase Price shall be denominated in the currency
of the primary economic environment of, either the Company or the Optionee (that is the functional currency of the Company or
the currency in which the Optionee is paid) as determined by the Company.

 

		9.	ADJUSTMENTS

 

			Upon the occurrence of any of the following described
events, Optionee's rights to purchase Shares under the ISOP shall be adjusted as hereafter
provided:

  

		9.1	In the event of a Transaction, the unexercised Options then outstanding under the ISOP shall be
assumed, or substituted for an appropriate number of shares of each class of shares or other securities of the Successor Company
(or a parent or subsidiary of the Successor Company) as were distributed to the shareholders of the Company in respect of the Transaction.
In the case of such assumption and/or substitution of shares, appropriate adjustments shall be made to the Purchase Price to reflect
such action, and all other terms and conditions of the Option Agreements, such as the Vesting Dates, shall remain in force, subject
to the sole discretion of the Committee.

    	10

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		9.2	Notwithstanding the above and subject to any applicable
law, the Board or the Committee shall have full power and authority to determine that in certain Option Agreements there shall
be a clause instructing that, if in any such Transaction as described in section 9.1 above, the Successor Company (or parent or
subsidiary of the Successor Company) does not agree to assume or substitute for the Options the Vesting Dates shall be accelerated
so that any unvested Option or any portion thereof shall be immediately vested as of the date which is ten (10) days prior to
the effective date of the Transaction.

 

		9.3	For the purposes
of section 9.1 above, an Option shall be considered assumed or substituted
if, following the Transaction, the Option confers the right to purchase or receive,
for each Share underlying an Option immediately prior to the Transaction, the consideration
(whether shares, options, cash, or other securities or property) received in the
Transaction by the shareholders for each share held on the effective date of the Transaction
(and if such holders were offered a choice of consideration, the type of consideration
chosen by the holders of a majority of the outstanding shares); provided, however,
that if such consideration received in the Transaction is not solely ordinary shares
(or their equivalent) of the Successor Company or its parent or subsidiary, the Committee
may, with the consent of the Successor Company, provide for the consideration
to be received upon the exercise of the Option to be solely ordinary shares (or
their equivalent) of the Successor Company or its parent or subsidiary equal in Fair Market
Value to the per share consideration received by holders of a majority of the outstanding
shares in the Transaction; and provided further that the Committee may determine,
that in lieu of such assumption or substitution of Options for options of the Successor
Company or its parent or subsidiary, such Options will be substituted for any other type of
asset or property including cash which is fair under the circumstances.

  

		9.4	If the Company is voluntarily liquidated or dissolved
while unexercised Options remain outstanding under the USSOP, the Company shall immediately notify all unexercised Option holders
of such liquidation, and the Option holders shall then have ten (10) days to exercise any unexercised Vested Option held by them
at that time, in accordance with the exercise procedure set forth herein. Upon the expiration of such ten-days period, all remaining
outstanding Options will terminate immediately.

  

		9.5	If the outstanding shares of the Company shall at any
time be changed or exchanged by declaration of a share dividend (bonus shares), share split, combination or exchange of shares,
recapitalization, or any other like event by or of the Company, and as often as the same shall occur, then the number, class and
kind of the Shares subject to the ISOP or subject to any Options therefore granted, and the Purchase Prices, shall be appropriately
and equitably adjusted so as to maintain the proportionate number of Shares without changing the aggregate Purchase Price, provided,
however, that no adjustment shall be made by reason of the distribution of subscription rights (rights offering) on outstanding
share. Upon happening of any of the foregoing, the class and aggregate number of Shares issuable pursuant to the ISOP (as set
forth in paragraph 7 hereof), in respect of which Options have not yet been exercised, shall be appropriately adjusted, all as
will be determined by the Board whose determination shall be final.

 

    	11

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

  

		9.6	Anything herein to the contrary notwithstanding, if prior
to the completion of an IPO all or substantially all of the shares of the Company are to be sold, or in case of a Transaction,
all or substantially all of the shares of the Company are to be exchanged for securities of another Company, then each Optionee
shall be obliged to sell or exchange, as the case may be, any Shares such Optionee purchased under the ISOP, in accordance with
the instructions issued by the Board in connection with the Transaction, whose determination shall be final.

 

		10.	TERM AND EXERCISE OF OPTIONS

 

		10.1	Options shall be exercised by the Optionee by giving
written notice and the payment of the purchase price to the Company, in such form and method as may be determined by the Company
and when applicable, by the Trustee in accordance with the requirements of Section 102, which exercise shall be effective upon
receipt of such notice by the Company and the payment of the Purchase Price at its principal office. The notice shall specify
the number of Shares with respect to which the Option is being exercised.

 

		10.2	Options, to the extent not previously exercised, shall
terminate forthwith upon the earlier of: (i) the date set forth in Exhibit B to the Option Agreement; and (ii) the expiration
of any extended period in any of the events set forth in section 10.5 below.

 

		10.3	The Options may be exercised by the Optionee in whole
at any time or in part from time to time, to the extent that the Options become vested and exercisable, prior to the Expiration
Date, and provided that, subject to the provisions of section 10.5 below, the Optionee is employed by or providing services to
the Company or any of its Affiliates, at all times during the period beginning with the granting of the Option and ending upon
the date of exercise.

 

		10.4	Subject to the provisions of section 10.5 below, in the
event of termination of Optionee’s employment or services, with the Company or any of its Affiliates, all Options granted
to such Optionee will immediately expire. A notice of termination of employment or service shall be deemed to constitute termination
of employment or service.

 

		10.5	Notwithstanding anything to the contrary hereinabove,
an Option may be exercised after the date of termination of Optionee’s employment or services with the Company or any Affiliate
during an additional period of time beyond the date of such termination, but only with respect to the number of Vested Options
at the time of such termination according to the Vesting Dates of the Options, if:

 

		(i)	termination is without
Cause, in which event any Vested Option still in force and unexpired may be exercised within a period of ninety (90) days after
the date of such termination; or-

 

		(ii)	termination is the result
of death or disability of the Optionee, in which event any Vested Option still in force and unexpired may be exercised
within a period of twelve (12) months after the date of such termination; or
-

 

    	12

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		(iii)	prior to the date of such termination, the Committee
shall authorize an extension of the terms of all or part of the Vested Options beyond the date of such termination for a period
not to exceed the period during which the Options by their terms would otherwise have been exercisable.

 

			For avoidance of any doubt, if termination of employment
or service is for Cause, any outstanding unexercised Option, will immediately expire and terminate, and the Optionee shall not
have any right in connection to such outstanding Options.

 

		10.6	To avoid doubt, the holders of Options shall not have
any of the rights or privileges of shareholders of the Company in respect of any Shares purchasable upon the exercise of any part
of an Option, nor shall they be deemed to be a class of shareholders or creditors of the Company for purpose of the operation
of sections 350 and 351 of the Companies Law or any successor to such section, until registration of the Optionee as holder of
such Shares in the Company’s register of shareholders upon exercise of the Option in accordance with the provisions of the
ISOP, but in case of Options and Shares held by the Trustee, subject to the provisions of Section 6 of the ISOP.

 

		10.7	Any form of Option Agreement authorized by the ISOP may
contain such other provisions as the Committee may, from time to time, deem advisable.

 

		10.8	With respect to Unapproved 102 Option, if the Optionee
ceases to be employed by the Company or any Affiliate, the Optionee shall extend to the Company and/or its Affiliate a security
or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102 and
the rules, regulation or orders promulgated thereunder.

 

		10.9	Notwithstanding anything to the contrary herein above,
in the event of termination of Optionee’s employment or service with the Company or any Affiliate, when the employee continues
to provide services (or vice versa) to the Company or any Affiliate, the Options granted to such Optionee shall not be affected
by such change in the Optionee’s status, and the employee will be allowed to keep the Options pursuant to its original terms.

 

		11.	VESTING OF OPTIONS

 

		11.1	Subject to the provisions of the ISOP, each Option shall
vest following the Vesting Dates and for the number of Shares as shall be provided in the Option Agreement. However, no Option
shall be exercisable after the Expiration Date.

 

		11.2	An Option may be subject to such other terms and conditions
on the time or times when it may be exercised, as the Committee may deem appropriate. The vesting provisions of individual Options
may vary.

 

    	13

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

  

		12.	PURCHASE FOR INVESTMENT

 

			The Company’s obligation
to issue or allocate Shares upon exercise of an Option granted under the ISOP
is expressly conditioned upon (a) the Company’s completion of any registration or other
qualifications of such Shares under all applicable laws, rules and regulations or (b) representations
and undertakings by the Optionee (or his legal representative, heir or legatee, in the
event of the Optionee’s death) to assure that the sale of the Shares complies with any registration
exemption requirements which the Company in its sole discretion shall deem necessary
or advisable. Such required representations and undertakings may include representations
and agreements that such Optionee (or his legal representative, heir, or legatee): (a)
is purchasing such Shares for investment and not with any present intention of selling or otherwise
disposing thereof; and (b) agrees to have placed upon the face and reverse of any certificates
evidencing such Shares a legend setting forth (i) any representations and undertakings which
such Optionee has given to the Company or a reference thereto and (ii) that, prior
to effecting any sale or other disposition of any such Shares, the Optionee must furnish to the
Company an opinion of counsel, satisfactory to the Company, that such sale or disposition will
not violate the applicable laws, rules, and regulations, whether of the State of Israel or of the United
States or any other State having jurisdiction over the Company and the Optionee.

  

		13.	SHARES SUBJECT TO RIGHT OF FIRST REFUSAL

 

		13.1	Notwithstanding anything to the contrary in the Articles
of Association of the Company, none of the Optionees shall have a right of first refusal in relation with any sale of shares in
the Company.

 

		13.2	Unless otherwise determined by the Committee, until such
time as the Company shall complete an IPO, an Optionee shall not have the right to sell Shares issued upon the exercise of an
Option within six (6) months of the date of exercise of such Option or issuance of such Shares. After the lapse of such six months
period, until such time as the Company shall complete an IPO, the sale of Shares issuable upon the exercise of an Option shall
be subject to a right of first refusal in accordance with the provisions of the Company’s Articles of Association.

  

		14.	DIVIDENDS

 

			Subject to
the Company’s Articles of Association, with respect to all Shares (but excluding, for avoidance
of any doubt, any unexercised Options) issued upon the exercise of Options held by the
Optionee or by the Trustee, as the case may be, the Optionee shall be entitled to receive dividends
in accordance with the quantity of such Shares, and subject to any applicable taxation on
distribution of dividends, and when applicable subject to the provisions of Section 102 and the
rules, regulations or orders promulgated thereunder.

 

    	14

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		15.	RESTRICTIONS ON ASSIGNABILITY AND SALE OF OPTIONS

 

		15.1	No Option or any right with respect thereto, purchasable
hereunder, whether fully paid or not, shall be assignable, transferable or given as collateral or any right with respect to it
given to any third party whatsoever, and during the lifetime of the Optionee each and all of such Optionee's rights to purchase
Shares hereunder shall be exercisable only by the Optionee.
	 	 	 
	 	 	Any such action made directly or indirectly, for an
immediate validation or for a future one, shall be void.

 

		14.2	As long as the Shares are held by the Trustee on behalf
of the Optionee, all rights of the Optionee over the Shares are personal, can not be transferred, assigned, pledged or mortgaged,
other than by will or pursuant to the laws of descent and distribution.

 

		16.	EFFECTIVE DATE AND DURATION OF THE ISOP

 

			The ISOP shall be effective as of the date that it is adopted by the Board and shall
                                                                              terminate at the end of ten (10) years from such day of adoption.

 

		17.	AMENDMENTS OR TERMINATION

 

		17.1	The Board may at any time, but when applicable, after
consultation with the Trustee, amend, alter, suspend or terminate the ISOP.

 

		17.2	No amendment, alteration,
suspension or termination of the ISOP shall impair the rights of any Optionee,
unless mutually agreed otherwise between the Optionee and the Company, which agreement must
be in writing and signed by the Optionee and the Company. Termination of the
ISOP shall not affect the Committee’s ability to exercise the powers granted to it hereunder
with respect to Options granted under the ISOP prior to the date of such termination.

 

		17.3	In the event
of any inconsistency or contradiction between any term of provision contained
in the ISOP and any provisions contained in the Company’s Articles of Association, the
terms and provisions in the Articles of Association shall govern and supersede the terms and
provisions contained herein.

 

    	15

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		18.	GOVERNMENT REGULATIONS

 

			The ISOP, and the granting and exercise of
                                                                            Options hereunder, and the obligation of the Company to sell and deliver
                                                                            Shares under such Options, shall be subject to all applicable laws, rules,
                                                                            and regulations, whether of the State of Israel or of the United States or any other State having
                                                                            jurisdiction over the Company and the Optionee, including the registration of the Shares under
                                                                            the United States Securities Act of 1933, and the Ordinance and to such approvals by any governmental
                                                                            agencies or national securities exchanges as may be required. Nothing herein shall be
                                                                            deemed to require the Company to register the Shares under the securities laws of any jurisdiction.

 

		19.	CONTINUANCE OF EMPLOYMENT OR HIRED SERVICES

 

			Neither the
ISOP nor the Option Agreement with the Optionee shall impose any obligation on the
Company or an Affiliate thereof, to continue any Optionee in its employ or service, and nothing
in the ISOP or in any Option granted pursuant thereto shall confer upon any Optionee any
right to continue in the employ or service of the Company or an Affiliate thereof or restrict the
right of the Company or an Affiliate thereof to terminate such employment or service at any time.

 

		20.	GOVERNING LAW & JURISDICTION

 

			The ISOP
shall be governed by and construed and enforced in accordance with the requirements relating
to the administration of stock option plans under the laws of the State of Israel applicable to
contracts made and to be performed therein, without giving effect to the principles of conflict of
laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining
to the ISOP.

 

		21.	TAX CONSEQUENCES

 

		21.1	Any tax consequences arising from the grant or exercise
of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company and/or its Affiliates,
the Trustee or the Optionee), hereunder, shall be borne solely by the Optionee. The Company and/or its Affiliates and/or the Trustee
shall withhold taxes according to the requirements under the applicable laws, rules, and regulations, including withholding taxes
at source. Furthermore, the Optionee shall agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them
harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation,
liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Optionee.

 

		21.2	The Company and/or, when applicable, the Trustee shall
not be required to release any Share certificate to an Optionee until all required payments have been fully made.

 

    	16

    	 

    

 

ISRAELI SHARE OPTION PLAN

 

 

 

		21.3	To the extent provided by the terms of an Option Agreement,
the Optionee may satisfy any tax withholding obligation relating to the exercise or acquisition of Shares under an Option
by any of the following means (in addition to the Company’s right to withhold from
any compensation paid to the Optionee by the Company) or by a combination of such means: (i)
tendering a cash payment; (ii) subject to the Committee’s approval on the payment
date, authorizing the Company to withhold Shares from the Shares otherwise issuable
to the Optionee as a result of the exercise or acquisition of Shares under the Option in an
amount not to exceed the minimum amount of tax required to be withheld by law;
or (iii) subject to Committee approval on the payment date, delivering to the Company owned
and unencumbered Shares; provided that Shares acquired on exercise of Options have been held
for at least 6 months from the date of exercise.

 

		22.	NON-EXCLUSIVITY OF THE ISOP

 

The adoption of
the ISOP by the Board shall not be construed as amending, modifying or rescinding
any previously approved incentive arrangements or as creating any limitations on the power
of the Board to adopt such other incentive arrangements as it may deem desirable, including,
without limitation, the granting of Options otherwise than under the ISOP, and such arrangements
may be either applicable generally or only in specific cases. 

 

For the avoidance
of doubt, prior grant of options to Optionees of the Company under their employment
agreements, and not in the framework of any previous option plan, shall not be deemed an approved
incentive arrangement for the purpose of this section.

 

		23.	MULTIPLE AGREEMENTS

 

The terms of each
Option may differ from other Options granted under the ISOP at the same time, or at any other
time. The Board may also grant more than one Option to a given Optionee during
the term of the ISOP, either in addition to, or in substitution for, one or more Options previously
granted to that Optionee.

 

		24	LOCK-UP

 

The Optionee acknowledges
that in the event that the Company’s shares shall be registered for trading
in any public market, Optionee’s rights to sell the Shares may be subject to certain limitations
(including a lock-up period), as will be requested by the Company or its underwriters, and
the Optionee unconditionally agrees and accepts any such limitations. Without derogating from
the above, the Optionee shall abide by a lock-up for the following periods: (i) one hundred and
eighty (180) days beginning on the effective date of the registration statement pursuant to which
an IPO was effected; and (ii) ninety (90) days beginning on the effective date of any subsequent
underwritten registration of the Company’s equity securities.

 

    	17Exhibit 4. 4 

 

CONSULTING
AGREEMENT

 

CONSULTING
AGREEMENT (the “Agreement”), dated as of September 27, 2005, by and between CAN-FITE BIOPHARMA LTD., an Israeli Company,
whose address is 10 Bareket Street, Petach Tikva, Israel (the “Company”), and BioStrategics Consulting Ltd through
its President, Dr. Michael H. Silverman, whose place of business is 9 Elizabeth Road, Marblehead, MA, USA (the “CONSULTANT”).

 

WHEREAS,
the Company is currently engaged in the research and development of therapeutics that function through binding to or interacting
with adenosine receptors (the “Field”);

 

WHEREAS,
the CONSULTANT has the necessary know-how, qualifications and experience in the Field required in order to provide the consulting
services as herein set forth;

 

WHEREAS,
the Company desires to appoint the CONSULTANT as a Medical Director, and the CONSULTANT desires to be appointed by the Company,
as a consultant to the Company in a role of Medical Director and in connection thereof, to provide to the Company with medical
and clinical research and development consulting services in the Field (the “Services”), as hereinafter set
forth.

 

NOW
THEREFORE, in consideration of the mutual undertakings and premises herein contained, the parties hereto hereby agree as follows:

 

		1.	The Appointment

 

		1.1	Subject to the terms hereof, the Company hereby appoints the CONSULTANT, and the CONSULTANT hereby
agrees to be appointed by the Company as a CONSULTANT to the Company in connection with the Services to be provided by the CONSULTANT
pursuant to Section 2 hereof. In rendering the Services hereunder, the CONSULTANT shall be deemed to be, and he is, an independent
contractor, and neither this Agreement nor the performance of any of the terms hereof will or will be deemed to constitute or create
any other relationship between the Company and the CONSULTANT.

 

		1.2	Without
                                                           derogating from any other provision herein, the CONSULTANT
                                                           acknowledges and agrees that during the term hereof (a) the
                                                           Company is free at all times to appoint other consultants, or to use
                                                           its own employees, in connection with any
                                                           of the services to be provided by the CONSULTANT
                                                           pursuant to Section 2 hereof, and (b) the CONSULTANT
                                                           will exercise reasonable care and diligence
                                                           to prevent, and will not take, any action or condition which
                                                           could result in a conflict with, or prejudicial to, the interests of
                                                           the Company.

 

    	1

    	 

    

 

		2.	Representations of the CONSULTANT

 

The
CONSULANT hereby represents to the Company that:

 

		2.1	He has the know-how, experience, qualifications and capacity to provide the Services to the Company
in the Field as set forth in this Agreement.

 

		2.2	The execution, delivery and the terms of this Agreement (i) will not constitute a default or breach
of any agreement or other instrument to which the CONSULTANT in party or by which he is bound, and (ii) does not require the consent
of any person or entity.

 

		2.3	In performing his Services hereunder, the CONSULTANT shall not utilize any proprietary information
of any third party.

 

		2.4	He is not employed, providing consulting services, has rights of representation, marketing agency
or any other right whatsoever of any other company or entity which competes, directly or indirectly, with the Company and the business
currently carried on by the Company.

 

		2.5	He will not, now or in the future, have any claim or claims whatsoever to any right of any kind
except as set forth in this Agreement.

 

		2.6	To the best of his knowledge, this Agreement and the provision of the Services by the CONSULANT
are not in conflict and do not breach any law, rule or regulation that govern the CONSULTANT.

 

		3.	Extent and Scope of Services

 

		3.1	During the term hereof, the CONSULTANT shall provide the services to the Company, to the affairs
and business of the Company and during such period will provide the Company with such consulting services as may be reasonably
requested of it, from time to time, by the CEO of the Company or any other person or firm designated by the CEO. The consulting
concerns clinical and medical research and development activities within the Field.

 

		3.2	The CONSULTANT shall render the Services, as required by the Company, on such dates, at such time
as shall be required by the Company, from his home office, and/or any other location agreed upon between the parties.

 

		3.3	During the term hereof, the CONSULTANT shall keep the Company currently informed as to his activities
hereunder and shall, periodically, provide the Company with written reports setting forth the Services provided by him.

 

    	2

    	 

    

 

		3.4	The parties hereby agree that the CONSULTANT is not deemed to be an agent or a representative of
the Company and therefore does not possess any authority, whether actual or apparent, to represent the Company or to contractually
commit the Company in any way or manner.

 

		4.	Compensation

 

In
consideration of the services provided to the Company by the CONSULTANT hereunder, the Company shall compensate the CONSULTANT
as follows:

 

		4.1	The Company agrees to pay the CONSULTANT a Consulting fee of three hundred twenty-five US dollars
($325) per hour. The aforementioned notwithstanding, the maximal pay for any single day’s work, will not exceed US$ 2,600.

 

		4.3	It is agreed by the parties hereto that reasonable pre-approved expenses in written incurred by
the CONSULTANT in the discharge of his duties under this Agreement, including travel expenses will be borne by the Company, and
reimbursed forthwith on request.

 

		4.4	In calculating the time incurred by the CONSULTANT, traveling time shall not be included in the
calculation. In the reimbursement of expenses as set forth in Section 4.3 above, it is agreed that the Company will reimburse CONSULTANT
for air travel in a coach class or equivalent, unless agreed otherwise before a specific travel.

 

		4.5	Payment and reimbursement shall be made to such bank account, as the CONSULTANT will indicate,
within twenty-one (21) business days from the date of obtaining such invoices by the Company.

 

		4.6	The payment provided by this Agreement shall be made to the CONSULTANT after deduction of all taxes
and deductions at source required by law to be deducted. The parties hereto agree, that all taxes, social insurance payments, pension
payments, health insurance and any other such payments, shall be borne solely by the CONSULTANT. The Company shall not pay nor
be liable to pay any taxes upon the payment to the CONSULTANT of any remuneration as set forth in this Agreement. CONSULTANT hereby
undertakes to indemnify and reimburse the Company for any amounts claimed or levied on the Company due to taxes, social insurance
payments, pension payments, health insurance and any other such payments resulting from any payment made by the Company to the
CONSULTANT under this Agreement

 

		4.7	The Company shall not undertake any social insurance premiums, pension payment and health insurance
on the name of the CONSULTANT.

 

    	3

    	 

    

 

		4.8	The CONSULTANT shall undertake, at his own expense, sufficient insurance coverage against illness,
injuries and/or damages incurred by him in connection of his render of services in accordance with this Agreement.

 

		5.	Confidential Information

 

		5.1	In the course of providing services
                                                           to the Company hereunder, The CONSULTANT may have access to, and become
                                                           familiar with, “Confidential Information” of the Company
                                                           (as hereinafter defined). The CONSULTANT shall at all times hereinafter
                                                           maintain in the strictest confidence all such Confidential Information
                                                           and shall not divulge any Confidential Information to any person, firm
                                                           or corporation with the prior written consent of the Company. For purposes
                                                           hereof, “Confidential Information” shall mean all
                                                           information in any and all medium which is confidential by its nature,
                                                           including, without limitation, data, technology, know-how, inventions,
                                                           discoveries, designs, processes, formulations, models, and/or trade
                                                           and business secrets relating to any line of business in which the
                                                           Company is involved. Confidential Information will also include the
                                                           Company’s marketing and business plans relating to current, planned,
                                                           old or future products.

 

		5.2	The CONSULTANT shall not use Confidential
                                                           Information for, or in connection with, the development, manufacture
                                                           or the use of any product or for any other purpose whatsoever except
                                                           as and to the extent provided in
                                                           this Agreement or in any other subsequent agreement between the parties.

 

		5.3	Notwithstanding the foregoing, Confidential Information shall not include information which the
CONSULTANT can evidence to the Company by appropriate documentation; (i) is in, or enters the public domain otherwise than by reason
of a breach hereof by the CONSULTANT; (ii) is known by The CONSULTANT at the time of disclosure thereof by the Company; (iii) is
independently developed by the CONSULTANT without recourse to Confidential Information; or (iv) is rightfully transmitted or disclosed
to the CONSULTANT by a third party which owes an obligation of confidentiality with respect to such information.

 

		5.4	All Confidential Information made available to, or received by, the CONSULTANT shall remain the
property of the company, and no license or other rights in or to the Confidential Information is granted hereby, the obligation
of the CONSULTANT is not to use any Confidential Information disclosed pursuant to this Agreement except as provided in this Agreement,
shall remain in effect indefinitely, and the CONSULTANT shall be prohibited from disclosing any such Confidential Information during
the term of this Agreement thereafter.

 

    	4

    	 

    

 

		5.5	All files, records, documents, drawings, specifications, equipment and similar items relating to
the business of the Company, whether prepared by the CONSULTANT or otherwise coming into his possession, and whether classified
as Confidential Information or not, shall remain the exclusive property of the Company. Upon termination or expiration of this
Agreement, or upon request by the Company, the CONSULTANT shall promptly turn over to the Company all such files, records, reports
analysis, documents and other material of any kind concerning the Company which the CONSULTANT obtained, received or prepared pursuant
to this Agreement.

 

		6.	Proprietary
                                                                                                   Information

 

		6.1	Definition of “Proprietary Information”. Contractor understands that the Company possesses
and will possess Proprietary Information which is important to its business or proposed business. In addition, Company frequently
conducts business and receives information from other parties with which it has a business relationship (collectively, “Business
Affiliates”) that is confidential in nature. For purposes of this Agreement, “Proprietary Information” is all information,
whether conveyed orally or in writing or in any other intangible or tangible form, that was or will be developed, created, or discovered
by or on behalf of the Company, or which became or will become known by, or was or is conveyed to the Company (including, without
limitation, “Results” as defined above), which has or may have commercial value to the Company or to the Company or to
Business Affiliates. “Proprietary Information” may include, but is not limited to, patents, copyrights, trade secrets,
techniques, data, databases, sketches, drawings, models, inventions (whether patentable or not), works of authorship, know-how,
processes, apparatus, equipment, formulae and confidential information related to the current future and proposed products and
services of the Company, and also includes, without limitation, Company’s respective information concerning research, clinical
studies, experimental work, development, design details and specifications, formulations, competitive analyses, chemical compounds
and variations thereof, excipients and other ingredients, masking and flavoring strategies, clinical and product development plans,
engineering, financial information, pricing, procurement requirements, purchasing, manufacturing, customer lists, business forecasts,
sales and merchandising and marketing plants and information, the duties, salaries and terms of compensation of employees or Business
Affiliates of the Company. “Proprietary Information” also includes proprietary or confidential information of any other
third party who may disclose such information to Company or Contractor in the course of Company’s business.

 

    	5

    	 

    

 

		6.2	Ownership of Proprietary information; Assignment. All ownership rights in Proprietary Information
and any other intellectual or industrial property of any sort anywhere in the world (collectively “Rights”) shall be
the sole and exclusive property of the Company. Contractor hereby assigns to the Company (and shall ensure any employees or agents
of Contractor shall assign) any Rights Contractor may have or acquire in such Proprietary Information by performing the Services
hereunder. At all times, both during the term of this Agreement and after its termination, Contractor will keep in confidence and
trust and will not use or disclose any Proprietary Information or anything related to it without the prior written consent of an
officer of the Company. Contractor shall take appropriate measures to ensure that its employees and agents, if any, arc bound to
the requirements set forth in such a manner that such party and/or its successor(s) will be able to honor its/their confidentiality
and nonuse obligations under this Agreement. Contractor acknowledges that any disclosure or unauthorized use of proprietary Information
will constitute a material breach of this Agreement and cause substantial harm to the Company for which monetary damages would
not be a fully adequate remedy and therefore, in the event of any such breach, in addition to any other available remedies, the
Company shall have the right to seek injunctive relief without the need to secure a bond

 

		7.	Non-Competition

 

		7.1	The CONSULTANT shall not at any time during the term
of this Agreement, directly or indirectly, engage in (as owner, stockholder,partner, director, officer, employee, consultant
or otherwise, except as an investor in a corporation whose stock is publicly traded and in which he holds less than 3% of the
outstanding shares) any business, which competes in any way with the Company’s business.

 

		7.2	The CONSULTANT shall not at any time during the term of this Agreement and for two (2) years thereafter,
solicit any employee, customer, or supplier of the Company to cease or change its legal or business relationship with the Company.

 

		8.	Terms and Termination

 

		8.1	Subject to provisions of Section 7.3 of this Agreement shall take effect from the date set out
above as of which this Agreement is deemed to be entered into and shall continue in full force and effect for a period of one (1)
year from such dale, Unless terminated as provided herein, the Agreement will be automatically renewed for consecutive one year
periods.

 

		8.2	Notwithstanding Section 7.1 above, either party may given notice to the other party terminating
this Agreement by providing the other party with thirty (30) days prior written notice. However, in accordance with the provisions
of Section 7.3 hereof, either party may given notice to the other party terminating this Agreement immediately upon the occurrence
of the events specified in Section 7.3 below.

 

		8.3	(a)     The Company shall have the right to terminate this Agreement “for
cause”, at any time, by giving the CONSULTANT notice of termination “for cause”, slating the reasons constituting
the “cause”. In such event, this Agreement shall be terminated as to the lime of delivery of the said notice. For purposes
hereof “cause” shall mean (a) a breach of trust by the CONSULTANT, including without limitation, acts of moral turpitude,
theft, embezzlement or self-dealing; (b) the disclosure of Confidential Information of or in relation to the Company to any third
party; or (c) material breach by the CONSULTANT of this Agreement, such breach not remedied within (30) thirty days after service
of notice by the Company on the CONSULTANT specifying the breach complained or and (if remediable) requiring remedy of it.

  

    	6

    	 

    

 

(b)     The
CONSULTANT shall have the right to terminate this Agreement “for cause”, at any lime, by giving to the Company notice
of termination “for cause”, stating specifically the reasons constituting the “cause”, in such event, this
Agreement shall be terminated as of the time of delivery of the said Notice. For the purposes hereof “cause” shall mean
(a) a material breach by the Company of this Agreement which breach shall not have been remedied within (30) thirty days of service
of a notice in writing by the CONSULTANT on the Company requiring remedy of such breach; or (b) the Company becoming bankrupt or
insolvent or ceasing or threatening to cease to carry on business or being unable to pay its debts as they fall due or a receiver
or other encumbrances being appointed to the undertaking and assets, or any material part thereof of the Company; or (c) a change
in the controlling shareholders of the Company, such that persons not currently controlling the Company become controlling shareholders
of the Company. For the purpose of this section, the term “control” means controlling the management of the Company
by either (1) holding or owning more than 50% of the voting shares of the Company, or (2) having the right to designate more than
50% of the directors of the Company.

 

		9.	Miscellaneous

 

		9.1	Any notice under this Agreement shall be in writing, to the addresses of the Company or the CONSULTANT
as set out above, and shall be deemed to have been duly given for all purposes (ft) seven (7) days after delivery of documents
to a courier such as FedEx for dispatch to either party; or (b) upon manual delivery, to the respective addresses or faxes set
forth above or to such other address of which notice as aforesaid has actually been received.

 

		9.2	This Agreement is the entire agreement between the parlies with respect to the subject matter hereof,
and supersedes all prior understandings, agreements and discussions between them, either written or oral, with respect to such
subject matter.

 

		9.3	This Agreement shall not be modified or amended except by a written instrument signed by the parties
hereto. No waiver or failure to act with respect to any breach or default hereunder, subsequent breach or default, whether of similar
or of different nature.

 

		9.4	This Agreement shall be governed by, interpreted and construed in accordance with the laws of the
State of Israel. The competent court in Tel Aviv, Israel shall have sole and exclusive jurisdiction regarding any dispute or claim
arising hereunder.

 

    	7

    	 

    

 

		9.5	Unless provided to the contrary in this Agreement, the CONSULTANT shall not assign this Agreement
to any third party, in whole or in part. The Company may assign this Agreement to any of its affiliate, upon the provision of written
notice to the CONSULTANT.

 

		9.6	Any provision hereof which is found to be invalid, illegal or unenforceable under any applicable
provision of valid laws, shall be amended to the extent required to render it valid, legal and enforceable under such laws (or
deleted if no such amendment is feasible), and such amendment or deletion shall not effect the enforceability of the other provisions
hereof.

 

		9.7	The Parties agree that failure of either party at any time to require performance by the other
Party of any of the provisions herein shall not operate as a waiver of the right of that party to request siriet performance of
the same or like provisions, or any other provisions hereof, at a later time.

 

IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.

 

	CAN-FITE BioPharma Ltd.	 	The CONSULTANT
	 	 	 	 	 
	By: 	/s/ Pnina Fishman	 	By:	/s/ Michael H. Silverman
	Dr. Pnina Fishman	 	Dr. Michael H. Silverman

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]